がん免疫療法 - 暇つぶしWikipedia

がん免疫療法

□記事を途中から表示しています
[最初から表示]

脚注 ^ a b 奥野清隆「がん免疫療法の歴史」（中村祐輔編「がんペプチドワクチン療法」中山書店2009 p.13~20 )
^ a b “「腸内細菌」ががん免疫療法の効果に影響。最新研究で分かった、より治療効果を得るポイント”. 再発転移がん治療情報. 2023年2月21日閲覧。
^ “【最新研究】あの食事でがん治療効果がアップ！食べものが癌の治療成績と生存率に影響するエビデンス”. がん情報チャンネル・がん治療認定医、外科学会指導医、消化器外科学会指導医、膵臓学会指導医佐藤典宏. 2023年2月21日閲覧。
^ 中村祐輔編「がんペプチドワクチン療法」中山書店2009 p.6
^ Strebhardt K, Ullrich A (Jun 2008). “Paul Ehrlich's magic bullet concept: 100 years of progress”. Nature Reviews. Cancer 8 (6): 473?80. doi:10.1038/nrc2394. .mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation.cs-ja1 q,.mw-parser-output .citation.cs-ja2 q{quotes:"「""」""『""』"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:#d33}.mw-parser-output .cs1-visible-error{color:#d33}.mw-parser-output .cs1-maint{display:none;color:#3a3;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}PMID 18469827.
^ Waldmann TA (Mar 2003). “Immunotherapy: past, present and future”. Nature Medicine 9 (3): 269?77. doi:10.1038/nm0303-269. PMID 12612576.
^ a b Palucka K, Banchereau J (Jul 2013). “Dendritic-cell-based therapeutic cancer vaccines”. Immunity 39 (1): 38?48. doi:10.1016/j.immuni.2013.07.004. PMID 23890062.
^ “がんの樹状細胞ワクチン療法”. 松本歯科大学. 2015年8月29日時点の ⇒オリジナルよりアーカイブ。2015年10月13日閲覧。
^ Gardner TA, Elzey BD, Hahn NM (Apr 2012). “Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer”. Human Vaccines & Immunotherapeutics 8 (4): 534?9. doi:10.4161/hv.19795. PMID 22832254.
^ Oudard S (May 2013). “Progress in emerging therapies for advanced prostate cancer”. Cancer Treatment Reviews 39 (3): 275?89. doi:10.1016/j.ctrv.2012.09.005. PMID 23107383.
^ Sims RB (Jun 2012). “Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer”. Vaccine 30 (29): 4394?7. doi:10.1016/j.vaccine.2011.11.058. PMID 22122856.
^ Shore ND, Mantz CA, Dosoretz DE, Fernandez E, Myslicki FA, McCoy C, Finkelstein SE, Fishman MN (Jan 2013). “Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer”. Cancer Control 20 (1): 7?16. PMID 23302902.
^ Scott AM, Wolchok JD, Old LJ (Apr 2012). “Antibody therapy of cancer”. Nature Reviews. Cancer 12 (4): 278?87. doi:10.1038/nrc3236. PMID 22437872.
^ a b Harding FA, Stickler MM, Razo J, DuBridge RB (May?Jun 2010). “The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions”. mAbs 2 (3): 256?65. doi:10.4161/mabs.2.3.11641. PMID 20400861.
^ Weiner LM, Surana R, Wang S (May 2010). “Monoclonal antibodies: versatile platforms for cancer immunotherapy”. Nature Reviews. Immunology 10 (5): 317?27. doi:10.1038/nri2744. PMID 20414205.
^ Seidel UJ, Schlegel P, Lang P (2013). “Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies”. Frontiers in Immunology 4: 76. doi:10.3389/fimmu.2013.00076. PMID 23543707.
^ Gelderman KA, Tomlinson S, Ross GD, Gorter A (Mar 2004). “Complement function in mAb-mediated cancer immunotherapy”. Trends in Immunology 25 (3): 158?64. doi:10.1016/j.it.2004.01.008. PMID 15036044.
^ Pardoll DM (Apr 2012). “The blockade of immune checkpoints in cancer immunotherapy”. Nature Reviews. Cancer 12 (4): 252?64. doi:10.1038/nrc3239. PMID 22437870.
^ Pardoll DM (Apr 2012). “The blockade of immune checkpoints in cancer immunotherapy”. Nature Reviews. Cancer 12 (4): 252?64. doi:10.1038/nrc3239. PMID 22437870.
^ a b Dranoff G (Jan 2004). “Cytokines in cancer pathogenesis and cancer therapy”. Nature Reviews. Cancer 4 (1): 11?22. doi:10.1038/nrc1252. PMID 14708024.
^ Dunn GP, Koebel CM, Schreiber RD (Nov 2006). “Interferons, immunity and cancer immunoediting”. Nature Reviews. Immunology 6 (11): 836?48. doi:10.1038/nri1961. PMID 17063185.
^ Lasfar A, Abushahba W, Balan M, Cohen-Solal KA (2011). “Interferon lambda: a new sword in cancer immunotherapy”. Clinical & Developmental Immunology 2011: 349575. doi:10.1155/2011/349575. PMID 22190970.
^ Coventry BJ, Ashdown ML (2012). “The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses”. Cancer Management and Research 4: 215?21. doi:10.2147/cmar.s33979. PMC 3421468. PMID 22904643. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3421468/.
^ a b 千原呉郎「抗癌剤の現状と将来.特に生薬薬理の観点から」『藥學雜誌』第108巻第3号、日本薬学会、1988年、171-186頁、doi:10.1248/yakushi1947.108.3_171、ISSN 0031-6903、NAID 110003648628。
^ American Cancer Society. ⇒Coriolus Versicolor Archived 2010年6月25日, at the Wayback Machine. Last Medical Review: 11/01/2008. Last Revised: 11/01/2008. Accessed May 10, 2014
^ B-Lymphocyte-Stimulating Polysaccharide from Mushroom Phellinus linteus. 43. (1985). p. 2105-2108. doi:10.1248/cpb.43.2105Abstract. PMID 8582012.
^ a b Restifo NP, Dudley ME, Rosenberg SA (Apr 2012). “Adoptive immunotherapy for cancer: harnessing the T cell response”. Nature Reviews. Immunology 12 (4): 269?81. doi:10.1038/nri3191. PMID 22437939.

次ページ

記事の検索

Size:66 KB
出典: フリー百科事典『ウィキペディア（Wikipedia）』
担当:undef